PRIA Logo™
HR8553119th CongressWALLET

POPCaP Authorization Act of 2026

Sponsored By: Representative Murphy, Gregory F. [R-NC-3]

In Committee

Summary

Creates a VA precision oncology program for prostate cancer. The bill would set up Centers of Excellence, a national leadership team, and a coordinated genetic sequencing and clinical trial network to expand veteran access to targeted cancer care.

Show full summary
  • Veterans: Enrollment would be limited to veterans in the VA patient enrollment system diagnosed with prostate or other genitourinary cancers. The program would offer trial enrollment and travel support to help veterans reach studies.
  • VA medical centers and staff: The Secretary would designate at least 21 Centers of Excellence, including one in each Veterans Integrated Service Network. Each Center must run genetic sequencing, a tumor board, a prostate cancer registry, metastasis biopsy capability, and employ key specialists plus two full-time research staff.
  • Research and oversight: A Program Leadership Team based in Seattle would create a uniform sequencing platform, coordinate trials with the National Cancer Institute and industry, maintain a public registry, and require annual reports and periodic performance reviews.

*Would increase federal spending by $15.5 million in each of fiscal years 2027, 2028, and 2029 to carry out the program.*

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

New VA prostate cancer program for veterans

If enacted, the VA would create a precision oncology program for prostate and related genitourinary cancers within 180 days. Program leadership would be based at the Seattle VA Medical Center and stay designated through at least 2033. The VA would keep at least 21 Centers of Excellence (one per VISN) with at least seven having genitourinary programs; each Center must staff specific cancer specialists and research personnel and follow uniform sequencing, registry, telemedicine, and trial participation rules. Veterans enrolled in the VA patient enrollment system under 38 U.S.C. 1705 with prostate or other genitourinary cancers would be eligible for Program services. The bill would authorize Congress to appropriate $15.5 million per year for each of FY2027–FY2029, require an implementation plan within 60 days, and require annual Program reports by March 1. The VA would be barred from cutting Centers' funding below the January 1, 2023 level and from removing prostate-cancer staff, programs, or functions that existed on January 1, 2023 until January 1, 2030.

Sponsors & CoSponsors

Sponsor

Murphy, Gregory F. [R-NC-3]

NC • R

Cosponsors

  • Rep. Conaway, Herbert C. [D-NJ-3]

    NJ • D

    Sponsored 4/28/2026

  • Rep. Riley, Josh [D-NY-19]

    NY • D

    Sponsored 7/30/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation